Case Reports Journal Article Epublish
PubMed: 41487566 DOI: 10.3389/fonc.2025.1727289
Case Report: Expansion of the POLD1-related polymerase proofreading-associated polyposis spectrum: first report of duodenal adenocarcinomas and characterization of two likely pathogenic variants.
Front Oncol 15:1727289
Authors: Anais Folletet, Morgane Helyon, Maud Privat, Nancy Uhrhammer, Mathilde Gay-Bellile, Mathias Cavaille, Flora Ponelle-Chachuat, Yannick Bidet, Mathis Lepage
Affiliations
- Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
- Digestive Oncology Department, Clermont Ferrand University Hospital, Clermont-Ferrand, France.
- INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, Clermont-Ferrand, France.
Abstract
BACKGROUND
Polymerase proofreading-associated polyposis (PPAP) is a rare autosomal dominant cancer predisposition syndrome caused by germline pathogenic variants in POLE or POLD1. While colorectal and endometrial cancers are the most frequent manifestations, the full tumor spectrum of POLD1-related PPAP remains incompletely defined.
CASE PRESENTATION
We describe two families carrying germline POLD1 variants classified as likely pathogenic. A novel missense variant c.1481T>G p.(Ile494Ser) and a recurrent missense variant c.1204G>A p.(Asp402Asn) were identified within the exonuclease domain. Both variants exhibited features consistent with pathogenicity, including high tumor mutational burden (TMB) and SBS10d mutational signature. Affected carriers developed colorectal and endometrial cancers, but also duodenal adenocarcinomas: this is the first report of this tumor type in germline POLD1 carriers.
CONCLUSIONS
Our report expands both the phenotypic and molecular spectrum of POLD1-associated PPAP by documenting the first duodenal adenocarcinomas in germline carriers and describing a novel variant. These findings emphasize the need for systematic upper gastrointestinal surveillance, support the systematic reporting of rare POLD1 variants to refine genotype-phenotype correlations, and underline the potential therapeutic relevance of identifying carriers in the context of immunotherapy.
MeSH
Neoplasms, Adenocarcinoma, Immunotherapy